Does the media prefer SANA or LEGN?

In the previous week, Legend Biotech had 4 more articles in the media than Sana Biotechnology. MarketBeat recorded 5 mentions for Legend Biotech and 1 mentions for Sana Biotechnology. Legend Biotech's average media sentiment score of 1.03 beat Sana Biotechnology's score of 0.00 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Legend Biotech 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, SANA or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Sana Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A Telix Pharmaceuticals $803.79M 4.99 -$7.12M N/A N/A

Is SANA or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -108.01% -40.68% Telix Pharmaceuticals N/A N/A N/A

Does the media prefer SANA or TLX?

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than Sana Biotechnology. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 1 mentions for Sana Biotechnology. Telix Pharmaceuticals' average media sentiment score of 0.08 beat Sana Biotechnology's score of 0.00 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Telix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, SANA or ELVN?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A

Is SANA or ELVN more profitable?

Enliven Therapeutics' return on equity of -18.55% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -108.01% -40.68% Enliven Therapeutics N/A -18.55% -18.09%

Does the media prefer SANA or ELVN?

In the previous week, Enliven Therapeutics had 17 more articles in the media than Sana Biotechnology. MarketBeat recorded 18 mentions for Enliven Therapeutics and 1 mentions for Sana Biotechnology. Enliven Therapeutics' average media sentiment score of 0.21 beat Sana Biotechnology's score of 0.00 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enliven Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GMTX or SANA?

Sana Biotechnology has a consensus target price of $9.50, indicating a potential upside of 158.50%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sana Biotechnology 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has higher earnings & valuation, GMTX or SANA?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A

Is GMTX or SANA more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Gemini Therapeutics N/A -38.78% -35.88% Sana Biotechnology N/A -108.01% -40.68%

Does the media favor NAMS or SANA?

In the previous week, NewAmsterdam Pharma had 22 more articles in the media than Sana Biotechnology. MarketBeat recorded 23 mentions for NewAmsterdam Pharma and 1 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.00 beat NewAmsterdam Pharma's score of -0.54 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 1 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Negative Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sana Biotechnology (SANA) Competitors

$3.62 +0.11 (+2.98%)

As of 12:03 PM Eastern

Compare

SANA vs. LEGN, TLX, ELVN, GMTX, and NAMS

Should you buy Sana Biotechnology stock or one of its competitors? MarketBeat compares Sana Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sana Biotechnology include Legend Biotech (LEGN), Telix Pharmaceuticals (TLX), Enliven Therapeutics (ELVN), Gemini Therapeutics (GMTX), and NewAmsterdam Pharma (NAMS). These companies are all part of the "biotechnology" industry.

How does Sana Biotechnology compare to Legend Biotech?

Sana Biotechnology (NASDAQ:SANA) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Sana Biotechnology currently has a consensus target price of $9.50, indicating a potential upside of 158.50%. Legend Biotech has a consensus target price of $55.29, indicating a potential upside of 165.75%. Given Legend Biotech's higher possible upside, analysts plainly believe Legend Biotech is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53

In the previous week, Legend Biotech had 4 more articles in the media than Sana Biotechnology. MarketBeat recorded 5 mentions for Legend Biotech and 1 mentions for Sana Biotechnology. Legend Biotech's average media sentiment score of 1.03 beat Sana Biotechnology's score of 0.00 indicating that Legend Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Legend Biotech	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sana Biotechnology has a net margin of 0.00% compared to Legend Biotech's net margin of -21.98%. Legend Biotech's return on equity of -24.92% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Legend Biotech	-21.98%	-24.92%	-14.87%

Sana Biotechnology has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Legend Biotech	$1.03B	3.76	-$296.80M	-$0.68	N/A

Sana Biotechnology has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Legend Biotech beats Sana Biotechnology on 8 of the 15 factors compared between the two stocks.

How does Sana Biotechnology compare to Telix Pharmaceuticals?

Sana Biotechnology (NASDAQ:SANA) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Sana Biotechnology has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than Sana Biotechnology. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 1 mentions for Sana Biotechnology. Telix Pharmaceuticals' average media sentiment score of 0.08 beat Sana Biotechnology's score of 0.00 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Telix Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.2% of Sana Biotechnology shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Telix Pharmaceuticals has higher revenue and earnings than Sana Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Telix Pharmaceuticals	$803.79M	4.99	-$7.12M	N/A	N/A

Telix Pharmaceuticals' return on equity of 0.00% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Telix Pharmaceuticals	N/A	N/A	N/A

Sana Biotechnology presently has a consensus target price of $9.50, suggesting a potential upside of 158.50%. Telix Pharmaceuticals has a consensus target price of $20.40, suggesting a potential upside of 72.73%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, research analysts plainly believe Sana Biotechnology is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

Summary

Telix Pharmaceuticals beats Sana Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Sana Biotechnology compare to Enliven Therapeutics?

Sana Biotechnology (NASDAQ:SANA) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

In the previous week, Enliven Therapeutics had 17 more articles in the media than Sana Biotechnology. MarketBeat recorded 18 mentions for Enliven Therapeutics and 1 mentions for Sana Biotechnology. Enliven Therapeutics' average media sentiment score of 0.21 beat Sana Biotechnology's score of 0.00 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enliven Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sana Biotechnology presently has a consensus price target of $9.50, suggesting a potential upside of 158.50%. Enliven Therapeutics has a consensus price target of $72.67, suggesting a potential upside of 21.89%. Given Sana Biotechnology's higher possible upside, research analysts plainly believe Sana Biotechnology is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Sana Biotechnology has a beta of 2.16, suggesting that its stock price is 116% more volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Enliven Therapeutics' return on equity of -18.55% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Enliven Therapeutics	N/A	-18.55%	-18.09%

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Summary

Enliven Therapeutics beats Sana Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Sana Biotechnology compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Sana Biotechnology (NASDAQ:SANA) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

Sana Biotechnology has a consensus target price of $9.50, indicating a potential upside of 158.50%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Sana Biotechnology had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 1 mentions for Sana Biotechnology and 0 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 0.00 equaled Sana Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Sana Biotechnology	Neutral

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market.

Gemini Therapeutics' return on equity of -38.78% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Sana Biotechnology	N/A	-108.01%	-40.68%

Summary

Sana Biotechnology beats Gemini Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Sana Biotechnology compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Sana Biotechnology (NASDAQ:SANA) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

In the previous week, NewAmsterdam Pharma had 22 more articles in the media than Sana Biotechnology. MarketBeat recorded 23 mentions for NewAmsterdam Pharma and 1 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.00 beat NewAmsterdam Pharma's score of -0.54 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	1 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Negative
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NewAmsterdam Pharma has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market.

NewAmsterdam Pharma currently has a consensus price target of $49.33, suggesting a potential upside of 76.05%. Sana Biotechnology has a consensus price target of $9.50, suggesting a potential upside of 158.50%. Given Sana Biotechnology's higher probable upside, analysts plainly believe Sana Biotechnology is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

NewAmsterdam Pharma has higher revenue and earnings than Sana Biotechnology. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$7.12M	460.03	-$203.82M	-$2.16	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

Sana Biotechnology has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%
Sana Biotechnology	N/A	-108.01%	-40.68%

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

NewAmsterdam Pharma beats Sana Biotechnology on 9 of the 16 factors compared between the two stocks.

Get Sana Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SANA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SANA vs. The Competition

Export

Metric	Sana Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.02B	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-3.95	9.06	269.91	24.87
Price / Sales	N/A	1,278.42	654.69	108.21
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	6.13	17.97	11.40	6.45
Net Income	-$244.17M	-$13.25M	$3.45B	$347.50M
7 Day Performance	15.57%	5.58%	3.66%	3.77%
1 Month Performance	-4.55%	-1.60%	-0.49%	-0.40%
1 Year Performance	22.50%	61.32%	77.51%	23.55%

Sana Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SANA Sana Biotechnology	1.5518 of 5 stars	$3.63 +3.0%	$9.50 +162.1%	+17.3%	$1.01B	N/A	N/A	380
LEGN Legend Biotech	3.4791 of 5 stars	$19.01 +2.5%	$55.29 +190.8%	-43.9%	$3.45B	$1.03B	N/A	2,965	Positive News Upcoming Earnings
TLX Telix Pharmaceuticals	4.1222 of 5 stars	$10.02 +1.3%	$20.40 +103.6%	+1.6%	$3.36B	$803.79M	N/A	1,184
ELVN Enliven Therapeutics	2.5964 of 5 stars	$58.04 +5.9%	$70.50 +21.5%	+241.8%	$3.34B	N/A	N/A	50	Earnings Report Analyst Downgrade High Trading Volume
GMTX Gemini Therapeutics	N/A	$77.00 -2.8%	N/A	+33.4%	$3.34B	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SANA) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sana Biotechnology (SANA) Competitors

SANA vs. LEGN, TLX, ELVN, GMTX, and NAMS

How does Sana Biotechnology compare to Legend Biotech?

Summary

How does Sana Biotechnology compare to Telix Pharmaceuticals?

Summary

How does Sana Biotechnology compare to Enliven Therapeutics?

Summary

How does Sana Biotechnology compare to Gemini Therapeutics?

Summary

How does Sana Biotechnology compare to NewAmsterdam Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA vs. The Competition

Sana Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sana Biotechnology (SANA) Competitors

SANA vs. LEGN, TLX, ELVN, GMTX, and NAMS

How does Sana Biotechnology compare to Legend Biotech?

Do analysts recommend SANA or LEGN?

Does the media prefer SANA or LEGN?

Is SANA or LEGN more profitable?

Which has preferable valuation & earnings, SANA or LEGN?

Which has more risk & volatility, SANA or LEGN?

Do institutionals and insiders believe in SANA or LEGN?

Summary

How does Sana Biotechnology compare to Telix Pharmaceuticals?

Which has more risk and volatility, SANA or TLX?

Does the media prefer SANA or TLX?

Do insiders & institutionals hold more shares of SANA or TLX?

Which has stronger valuation & earnings, SANA or TLX?

Is SANA or TLX more profitable?

Do analysts prefer SANA or TLX?

Summary

How does Sana Biotechnology compare to Enliven Therapeutics?

Does the media prefer SANA or ELVN?

Do analysts rate SANA or ELVN?

Do institutionals and insiders hold more shares of SANA or ELVN?

Which has more risk and volatility, SANA or ELVN?

Is SANA or ELVN more profitable?

Which has better earnings & valuation, SANA or ELVN?

Summary

How does Sana Biotechnology compare to Gemini Therapeutics?

Which has higher earnings & valuation, GMTX or SANA?

Do analysts recommend GMTX or SANA?

Does the media refer more to GMTX or SANA?

Do insiders and institutionals hold more shares of GMTX or SANA?

Which has more volatility & risk, GMTX or SANA?

Is GMTX or SANA more profitable?

Summary

How does Sana Biotechnology compare to NewAmsterdam Pharma?

Does the media favor NAMS or SANA?

Which has more volatility & risk, NAMS or SANA?

Do analysts prefer NAMS or SANA?

Which has higher valuation and earnings, NAMS or SANA?

Is NAMS or SANA more profitable?

Do institutionals & insiders hold more shares of NAMS or SANA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA vs. The Competition

Sana Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools